AstraZeneca’s Fasenra gets FDA ODD status for eosinophilic oesophagitis

This article was originally published here

Fasenra, which was developed by AstraZeneca’s MedImmune, was in-licensed from BioWa, a subsidiary of Japan-based Kyowa Hakko Kirin. Prior to receiving the orphan drug designation for eosinophilic oesophagitis,

The post AstraZeneca’s Fasenra gets FDA ODD status for eosinophilic oesophagitis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply